Gaucher Disease Types
Gaucher disease is classified into three distinct clinical types based on the presence and severity of neurological involvement: Type 1 (non-neuronopathic), Type 2 (acute infantile neuronopathic), and Type 3 (chronic neuronopathic), with Type 1 being the most common form in the United States and distinguished by its limited neurological involvement. 1
Type 1 Gaucher Disease (Non-Neuronopathic)
Type 1 represents approximately 90% of cases in the United States and Europe, though less in other regions 2. This form is characterized by the absence of primary central nervous system involvement 1.
Clinical Features:
- Hepatosplenomegaly (often massive)
- Thrombocytopenia (bleeding tendency)
- Anemia
- Bone involvement (bone pain, crises, avascular necrosis, osteopenia)
- Growth delay in children
- Pulmonary involvement (less common)
- Age of onset: childhood to late adulthood 1
Critical Long-term Risks:
- Increased risk of multiple myeloma
- Increased risk of Parkinsonism 1
Treatment:
FDA-approved enzyme replacement therapy (ERT) with imiglucerase, velaglucerase alfa, or taliglucerase alfa, and substrate reduction therapy (SRT) with miglustat or eliglustat are effective for Type 1 disease 1.
Type 2 Gaucher Disease (Acute Infantile Neuronopathic)
Type 2 accounts for approximately 1% of cases in the United States 1. This is the most severe form with a rapidly progressive and often fatal course 1.
Clinical Features:
- Neonatal hydrops fetalis (can present prenatally)
- Collodion baby phenotype (in some cases) 3
- Severe neurological manifestations:
- Seizures
- Bulbar palsy
- Hypertonia
- Supranuclear gaze palsy
- Hepatosplenomegaly
- Anemia and thrombocytopenia
- Interstitial lung disease
- Age of onset: typically within first few months of life 1
Prognosis and Treatment:
Type 2 disease is uniformly fatal, typically resulting in death within the first 2 years of life 3. Treatment is primarily supportive, as ERT and SRT are not effective for the neurological manifestations 1, 4. Recent data from Chinese children shows increased susceptibility to infections with respiratory failure from severe infections being a leading cause of death 5.
Type 3 Gaucher Disease (Chronic Neuronopathic)
Type 3 represents approximately 5% of cases in the United States 1. This form has a more variable and slowly progressive neurological course compared to Type 2 1.
Clinical Features:
- Hepatosplenomegaly
- Interstitial lung disease
- Anemia and thrombocytopenia
- Bone involvement
- Neurological manifestations (variable severity):
- Supranuclear gaze palsy
- Cataplexy
- Cerebellar ataxia
- Intellectual disability (in some cases)
- Neurodegeneration
- Age of onset: infantile-childhood 1
Treatment Considerations:
ERT and SRT are available for Type 3 disease and effectively treat systemic manifestations, but are generally not effective in ameliorating neurological manifestations 1. Some patients have received ERT followed by hematopoietic stem cell transplantation (HSCT) 6. Patients with Type 3 who receive no treatment or late ERT show unfavorable outcomes 6.
Important Clinical Pitfalls
Ethnic Considerations:
- Ashkenazi Jewish population: Type 1 disease incidence as high as 1 in 450 births 1
- Thai population: Neuronopathic forms (Types 2 and 3) are strikingly more prevalent, with Type 3 being most common (44.5%), followed by Type 2 (40.7%) 6
Genotype-Phenotype Correlation:
The correlation between genotype and phenotype is complex 7. Homozygosity for recombinant alleles is associated with early lethality 3. The L444P mutation is commonly found in Type 2 and severe Type 3 cases, particularly as part of recombinant alleles 6, 3.
Diagnostic Approach:
Diagnosis is confirmed by demonstrating low acid β-glucosidase enzyme activity together with biallelic pathogenic variants in the GBA gene and/or elevated lyso-Gb1 biomarker 1. Enzyme activity testing is the gold standard 7, 8.